The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors

Thrombocytopenia is common in cancer patients; it may be secondary to the malignancy itself, its treatment, or other etiologies, such as liver disease or infection. In the absence of any currently effective therapy to prevent thrombocytopenia, the usual clinical response is to decrease the dose and/